Table of Contents
Around 90% of solid-tumor immunotherapy programs fail - many due to poor target selection. But what if we could eliminate the guesswork?
Instead of relying on predictions, 3T Biosciences are measuring real human T cell responses - using functional screening to find peptide-HLA targets that activate T cells effectively.
Cross-reactivity can be avoided before programs reach the clinic - where failures can cost $100M+ per asset.
The 3T approach is now translating into:
- Shared intracellular targets (larger addressable populations)
- A lead pHLA/CD3 bispecific moving through IND-enabling toward 2026 clinic entry
- Earlier safety de-risking in a modality where toxicity has killed programs late
Onyx spoke with CEO Stefan J. Scherer at JPM 2026 to understand their platform fully.
A special thanks to HUMPHREYS LAW for sponsoring our JPM content!
Comments